ArticleInternational journal of cancer2011
MED29, a component of the mediator complex, possesses both oncogenic and tumor suppressive characteristics in pancreatic cancer.
Article in International journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- The Mediator Complex: From Transcriptional Regulation to Disease Pathogenesis.International journal of molecular sciences · 2026Review
- Biallelic MED29 variants cause pontocerebellar hypoplasia with cataracts.European journal of human genetics : EJHG · 2025Article
- Mediator-29 limits Caenorhabditis elegans fecundity.Genetics · 2025Article
- Article
- Identification of the role of MED6 in the development and prognosis of lung adenocarcinoma based on multi-omics profiling.Journal of Cancer · 2025Article
- CHRDL1 inhibits OSCC metastasis via MAPK signaling-mediated inhibition of MED29.Molecular medicine (Cambridge, Mass.) · 2024Article
- Traumatic brain injury promotes neurogenesis at the cost of astrogliogenesis in the adult hippocampus of male mice.Nature communications · 2024Article
- Cyclin-dependent kinase 19 upregulation correlates with an unfavorable prognosis in hepatocellular carcinoma.BMC gastroenterology · 2021Article
- Screening and functional identification of lncRNAs in antler mesenchymal and cartilage tissues using high-throughput sequencing.Scientific reports · 2020Article
- Transcription regulation by the Mediator complex.Nature reviews. Molecular cell biology · 2018Review
- Mediator independently orchestrates multiple steps of preinitiation complex assembly in vivo.Nucleic acids research · 2015Article
- Mediator Subunit Med28 Is Essential for Mouse Peri-Implantation Development and Pluripotency.PloS one · 2015Article
- Mediator links transcription and DNA repair by facilitating Rad2/XPG recruitment.Genes & development · 2013Article
- Mediator complex dependent regulation of cardiac development and disease.Genomics, proteomics & bioinformatics · 2013Review
- Dysregulation of the basal RNA polymerase transcription apparatus in cancer.Nature reviews. Cancer · 2013Review
- MoNetFamily: a web server to infer homologous modules and module-module interaction networks in vertebrates.Nucleic acids research · 2012Article
- Mediator and human disease.Seminars in cell & developmental biology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Mediator complex subunit 29 (MED29) is part of a large multiprotein coactivator complex that mediates regulatory signals from gene-specific activators to general transcription machinery in RNA polymerase II mediated transcription. We previously found that MED29 is amplified and overexpressed in pancreatic cancer and that MED29 silencing leads to decreased cell survival in PANC-1 pancreatic cancer cells with high MED29 expression. Here we further demonstrate decreased migration, invasion and colony formation in PANC-1 cells after MED29 silencing. Unexpectedly, lentiviral-based overexpression of MED29 led to decreased proliferation of NIH/3T3 cells as well as MIAPaCa-2 pancreatic cancer cells with low endogenous expression. More importantly, subcutaneous inoculation of the MED29-transduced pancreatic cancer cells into immuno-compromised mice resulted in dramatic tumor suppression. The mock-control mice developed large tumors, whereas the animals with MED29-xenografts showed both decreased tumor incidence and a major reduction in tumor size. Gene expression analysis in the MED29-transduced pancreatic cancer cells revealed differential expression of genes involved in control of cell cycle and cell division. The observed gene expression changes are expected to modulate the cell cycle in a way that leads to reduced cell growth, explaining the in vivo tumor suppressive phenotype. Taken together, these data implicate MED29 as an important regulator of key cellular functions in pancreatic cancer with both oncogenic and tumor suppressive characteristics. Such a dualistic role appears to be more common than previously thought and is likely to depend on the genetic background of the cancer cells and their surrounding environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.